https://researchdata.se/sv/catalogue Search results sv Datasetet består av digitiserade godartade prostata H&E-biopsier från män med förhöjda PSA-värden. För mer information, se beskrivning på engelska: This dataset comprises digitized benign prostate hematoxilyn and eosin (H&E) biopsies from men with raised prostate-specific antigen (PSA) values. The biopsies were systematically taken from different locations in the prostate and were not guided by magnetic resonance imaging (MRI). The dataset includes paired samples from patients with comparable age and PSA levels, all initially diagnosed as benign but with different outcomes upon subsequent follow-ups and re-biopsies. While some patients remained cancer-free during eight years of follow-up, others were diagnosed with prostate cancer within the subsequent 30 months of follow-up. The final processed dataset includes 213 patients from northern Sweden, resulting in a total of 587 H&E prostate needle biopsies. Among these, 125 control patients with 333 biopsies exhibited no cancer development in eight years following the initial diagnosis. Conversely, 88 case patients with 254 biopsies were diagnosed with PCa of various ISUP grades within the 30 months following the initial diagnosis. Each case patient is accompanied by one to three control patients, paired for similar age, PSA value and year of diagnosis. Patients were anonymized by assigning random case IDs and MRXS image files were anonymized by using the module in https://github.com/bgilbert/anonymize-slide. Mon, 17 Jun 2024 15:05:09 GMT https://researchdata.se/sv/catalogue/dataset/2024-144 https://researchdata.se/sv/catalogue/dataset/2024-144 Uppsala universitet Eduard Chelebian Carolina Wählby Anders Bergh MR-images of the prostate region from healthy volunteers acquired at Elekta unity MR-Linac at Uppsala University Hospital. Data from each volunteer consist of an initial T2-weighted scan, followed by a number of groups of paired low and high resolution data approximately 5 minutes apart with a 3D balanced steady state free precession sequence. The initial T2-image and all high resolution images are segmented by a single observer including prostate, bladder and rectum. Mon, 23 Jan 2023 00:00:00 GMT https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-lesser https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-lesser AIDA Data Hub Fransson, Samuel Strand, Robin Multi-echo gradient echo (MEGRE) MRI data with 8 different echo times (2.38-23.6 ms) from 326 + 40 prostate cancer patients with gold fiducial markers inserted into the prostate (train/validation + test dataset). A scientific paper that utilizes this dataset for deep learning has been [published](https://doi.org/10.1088/1361-6560/abb0f9). Underlying description of the technique and its first use has been described in a [previous publication](https://www.ncbi.nlm.nih.gov/pubmed/28803447). The data contains an image volume for each patient, for each echo time. The center of mass from the three inserted prostate gold fiducial markers was manually defined. The ground truth label for this dataset consist of spherical objects with a radius of 1-12 mm, inserted in the center of mass defined locations. Method in the paper uses 9 mm radius. Thu, 30 Apr 2020 00:00:00 GMT https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-megre https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-megre AIDA Data Hub Gustafsson, Christian Jamtheim 2611 scanned prostate biopsies from 460 patient cases sampled between 2015 and 2018. Annotation of clinical metadata and treatment decisions made in connection with biopsy sampling exist on case-level. Roughly 35% of the biopsies contain cancer. In-image annotations exists in macro images the form of ink markings from the clinical workflow. Thu, 30 Apr 2020 00:00:00 GMT https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-sprob20 https://researchdata.se/sv/catalogue/dataset/doi-10-23698-aida-sprob20 AIDA Data Hub Walhagen, Peter Röbeck, Pontus Bengtsson, Ewert Busch, Christer Häggman, Michael Bakgrund: Under de senaste åren har det skett en riskökning för infektion efter prostatabiopsi. Målet med studien var att kartlägga användningen av antibiotikaprofylax vid prostatabiopsi i Sverige. Metod: Alla enheter som rapporterar till nationella prostatacancerregistret fick en enkät om antibiotikaprofylax vid prostatabiopsi. Resultat: Svarsfrekvensen var 90% (76 av 84 enheter). När det gäller patienter utan riskfaktorer för infektion var en enkeldos ciprofloxacin 750 mg den vanligaste profylaxen och användes av 50 enheter (66%). Fjorton enheter (18%) använde flera doser ciprofloxacin 500 eller 750 mg och sju enheter (9%) använde en singeldos av trimetoprim/sulfametoxazol 160/800 mg. När det gäller patienter med riskfaktorer för infektion (tex KAD eller tidigare urinvägsinfektion) visade enkäten ett vitt spektrum av olika preparat och behandlingslängder. Urinsticka användes av 30 kliniker (39%) och de flesta kliniker gav profylaxen omedelbart innan biopsin (n=41, 54%). Lavemang gavs av 6 enheter (8%). Konklusion: Relativt god efterlevnad till nationella vårdprogrammet för prostatacancer visades för lågriskpatienter med hög användning av singeldos ciprofloxacin 750 mg. Emellertid visar de blandade svaren kring handläggning av riskpatienter att bristen på vägledning från nationella riktlinjer kan utgöra ett problem som leder till under- eller överbehandling. En ökad användning av urinsticka eller odling skulle kunna förbättra riskklassificeringen av patienter inför biopsi. Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). Mon, 20 Jan 2020 00:00:00 GMT https://researchdata.se/sv/catalogue/dataset/snd1137-1 https://researchdata.se/sv/catalogue/dataset/snd1137-1 Umeå universitet Johan Styrke